SCHEDULE 13G/A: Muneer Satter's Amended SEC Filing Reveals 0% Stake in Aadi Bioscience

Muneer A. Satter has filed an amended Schedule 13G for Aadi Bioscience, Inc., indicating a beneficial ownership of 0% of the company's common stock as of December 31, 2024.

Summary

• This document is an Amendment No. 2 to a Schedule 13G filing by Muneer A. Satter concerning Aadi Bioscience, Inc.
• As of December 31, 2024, Muneer A. Satter beneficially owns 659 shares of Aadi Bioscience, Inc. Common Stock.
• This ownership represents 0% of the total class of securities.
• Muneer A. Satter holds sole voting power and sole dispositive power over all 659 shares.
• The shares are held by an entity for which Muneer A. Satter serves as an investment advisor.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The sentiment is slightly negative due to the reduction of beneficial ownership to 0% by a previously reporting individual, which could signal a lack of confidence or divestment. However, it's a routine filing and doesn't contain adverse operational news about the company itself.

Positives

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of Aadi Bioscience, Inc., indicating no activist intent from this specific shareholder.

Negatives

• The beneficial ownership percentage has decreased to 0%, implying a complete divestment or a reduction below the 5% reporting threshold from a previous stake, which could be perceived negatively by the market.

Risks

• The reduction to 0% beneficial ownership by a previously reporting person could be interpreted as a lack of confidence or a shift in investment strategy regarding Aadi Bioscience, Inc., potentially leading to negative market sentiment or selling pressure on the stock.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Aadi Bioscience, Inc.'s future performance or strategy.

Industry Context

This filing is a routine disclosure of beneficial ownership changes. A reduction to 0% by a previously reporting holder (implied by 'Amendment No. 2') could be a data point for investors assessing institutional interest in Aadi Bioscience, Inc., a biotechnology company. Such changes are common in the dynamic biotech sector where investment theses can evolve rapidly based on clinical trial results, regulatory approvals, or broader market conditions.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G/A) and does not contain financial results or operational metrics that can be directly compared to industry standards or specific comparable companies/projects. Its primary purpose is to disclose beneficial ownership.

Stakeholder Impact

• Shareholders: The reduction in beneficial ownership to 0% by a previously reporting individual might lead to negative sentiment or increased selling pressure on the stock, potentially impacting share price.

Key Dates

Recommendation

Keywords

SEC filing, Schedule 13G, Aadi Bioscience, Muneer A. Satter, beneficial ownership, common stock, institutional ownership, equity stake, investment advisor